» Articles » PMID: 19114059

No Exit: Targeting the Budding Process to Inhibit Filovirus Replication

Overview
Journal Antiviral Res
Publisher Elsevier
Date 2008 Dec 31
PMID 19114059
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

The filoviruses, Ebola and Marburg, cause severe hemorrhagic fever in humans and nonhuman primates, with high mortality rates. Although the filovirus replication pathway is now understood in considerable detail, no antiviral drugs have yet been developed that directly inhibit steps in the replication cycle. One potential target is the filovirus VP40 matrix protein, the key viral protein that drives the budding process, in part by mediating specific virus-host interactions to facilitate the efficient release of virions from the infected cell. This review will summarize current knowledge of key structural and functional domains of VP40 believed to be necessary for efficient budding of virions and virus-like particles. A better understanding of the structure and function of these key regions of VP40 will be crucial, as they may represent novel and rational targets for inhibitors of filovirus egress.

Citing Articles

Research progress on the mechanism of exosome-mediated virus infection.

Zhang H, Liu X, Shi J, Su X, Xie J, Meng Q Front Cell Infect Microbiol. 2024; 14:1418168.

PMID: 38988816 PMC: 11233549. DOI: 10.3389/fcimb.2024.1418168.


Computational and experimental identification of keystone interactions in Ebola virus matrix protein VP40 dimer formation.

Narkhede Y, Saxena R, Sharma T, Conarty J, Ramirez V, Motsa B Protein Sci. 2024; 33(5):e4978.

PMID: 38591637 PMC: 11002992. DOI: 10.1002/pro.4978.


Role of phosphatidic acid lipids on plasma membrane association of the Ebola virus matrix protein VP40.

Cioffi M, Husby M, Gerstman B, Stahelin R, Chapagain P Biochim Biophys Acta Mol Cell Biol Lipids. 2024; 1869(3):159464.

PMID: 38360201 PMC: 11687635. DOI: 10.1016/j.bbalip.2024.159464.


Minor changes in electrostatics robustly increase VP40 membrane binding, assembly, and budding of Ebola virus matrix protein derived virus-like particles.

Motsa B, Sharma T, Chapagain P, Stahelin R bioRxiv. 2024; .

PMID: 38352396 PMC: 10862912. DOI: 10.1101/2024.01.30.578092.


Designing a novel multi‑epitope vaccine against Ebola virus using reverse vaccinology approach.

Alizadeh M, Amini-Khoei H, Tahmasebian S, Ghatrehsamani M, Samani K, Edalatpanah Y Sci Rep. 2022; 12(1):7757.

PMID: 35545650 PMC: 9094136. DOI: 10.1038/s41598-022-11851-z.


References
1.
Hartlieb B, Weissenhorn W . Filovirus assembly and budding. Virology. 2005; 344(1):64-70. DOI: 10.1016/j.virol.2005.09.018. View

2.
McCarthy S, Licata J, Harty R . A luciferase-based budding assay for Ebola virus. J Virol Methods. 2006; 137(1):115-9. DOI: 10.1016/j.jviromet.2006.06.007. View

3.
Sudol M, Chen H, Bougeret C, Einbond A, Bork P . Characterization of a novel protein-binding module--the WW domain. FEBS Lett. 1995; 369(1):67-71. DOI: 10.1016/0014-5793(95)00550-s. View

4.
Noda T, Sagara H, Suzuki E, Takada A, Kida H, Kawaoka Y . Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol. 2002; 76(10):4855-65. PMC: 136157. DOI: 10.1128/jvi.76.10.4855-4865.2002. View

5.
Krammer A, Kirchhoff P, Jiang X, Venkatachalam C, Waldman M . LigScore: a novel scoring function for predicting binding affinities. J Mol Graph Model. 2005; 23(5):395-407. DOI: 10.1016/j.jmgm.2004.11.007. View